537 related articles for article (PubMed ID: 26328624)
1. Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial.
Dunbar RL; Nicholls SJ; Maki KC; Roth EM; Orloff DG; Curcio D; Johnson J; Kling D; Davidson MH
Lipids Health Dis; 2015 Sep; 14():98. PubMed ID: 26328624
[TBL] [Abstract][Full Text] [Related]
2. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
Maki KC; Orloff DG; Nicholls SJ; Dunbar RL; Roth EM; Curcio D; Johnson J; Kling D; Davidson MH
Clin Ther; 2013 Sep; 35(9):1400-11.e1-3. PubMed ID: 23998969
[TBL] [Abstract][Full Text] [Related]
3. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
Kastelein JJ; Maki KC; Susekov A; Ezhov M; Nordestgaard BG; Machielse BN; Kling D; Davidson MH
J Clin Lipidol; 2014; 8(1):94-106. PubMed ID: 24528690
[TBL] [Abstract][Full Text] [Related]
4. The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia.
Morton AM; Furtado JD; Lee J; Amerine W; Davidson MH; Sacks FM
J Clin Lipidol; 2016; 10(6):1442-1451.e4. PubMed ID: 27919362
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
[TBL] [Abstract][Full Text] [Related]
6. N-3 polyunsaturated fatty acids improve lipoprotein particle size and concentration in Japanese patients with type 2 diabetes and hypertriglyceridemia: a pilot study.
Ide K; Koshizaka M; Tokuyama H; Tokuyama T; Ishikawa T; Maezawa Y; Takemoto M; Yokote K
Lipids Health Dis; 2018 Mar; 17(1):51. PubMed ID: 29544483
[TBL] [Abstract][Full Text] [Related]
7. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.
Maki KC; Bays HE; Dicklin MR; Johnson SL; Shabbout M
J Clin Lipidol; 2011; 5(6):483-92. PubMed ID: 22108152
[TBL] [Abstract][Full Text] [Related]
8. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.
Maki KC; McKenney JM; Reeves MS; Lubin BC; Dicklin MR
Am J Cardiol; 2008 Aug; 102(4):429-33. PubMed ID: 18678300
[TBL] [Abstract][Full Text] [Related]
9. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).
Bays HE; Braeckman RA; Ballantyne CM; Kastelein JJ; Otvos JD; Stirtan WG; Soni PN
J Clin Lipidol; 2012; 6(6):565-72. PubMed ID: 23312052
[TBL] [Abstract][Full Text] [Related]
10. Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial.
Stroes ESG; Susekov AV; de Bruin TWA; Kvarnström M; Yang H; Davidson MH
J Clin Lipidol; 2018; 12(2):321-330. PubMed ID: 29289538
[TBL] [Abstract][Full Text] [Related]
11. Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia.
Davidson MH; Maki KC; Bays H; Carter R; Ballantyne CM
J Clin Lipidol; 2009 Oct; 3(5):332-40. PubMed ID: 21291831
[TBL] [Abstract][Full Text] [Related]
12. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.
Nicholls SJ; Lincoff AM; Garcia M; Bash D; Ballantyne CM; Barter PJ; Davidson MH; Kastelein JJP; Koenig W; McGuire DK; Mozaffarian D; Ridker PM; Ray KK; Katona BG; Himmelmann A; Loss LE; Rensfeldt M; Lundström T; Agrawal R; Menon V; Wolski K; Nissen SE
JAMA; 2020 Dec; 324(22):2268-2280. PubMed ID: 33190147
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
Ballantyne CM; Bays HE; Kastelein JJ; Stein E; Isaacsohn JL; Braeckman RA; Soni PN
Am J Cardiol; 2012 Oct; 110(7):984-92. PubMed ID: 22819432
[TBL] [Abstract][Full Text] [Related]
14. Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study).
Ballantyne CM; Braeckman RA; Bays HE; Kastelein JJ; Otvos JD; Stirtan WG; Doyle RT; Soni PN; Juliano RA
J Clin Lipidol; 2015; 9(3):377-83. PubMed ID: 26073397
[TBL] [Abstract][Full Text] [Related]
15. N-3 fatty acid supplementation mediates lipid profile, including small dense LDL, when combined with statins: a randomized double blind placebo controlled trial.
Dogay Us G; Mushtaq S
Lipids Health Dis; 2022 Sep; 21(1):84. PubMed ID: 36050695
[TBL] [Abstract][Full Text] [Related]
16. Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study.
Dunbar RL; Gaudet D; Davidson M; Rensfeldt M; Yang H; Nilsson C; Kvarnström M; Oscarsson J
Lipids Health Dis; 2020 May; 19(1):117. PubMed ID: 32473640
[TBL] [Abstract][Full Text] [Related]
17. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
Le NA; Innis-Whitehouse W; Li X; Bakker-Arkema R; Black D; Brown WV
Metabolism; 2000 Feb; 49(2):167-77. PubMed ID: 10690940
[TBL] [Abstract][Full Text] [Related]
18. Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study).
Miller M; Ballantyne CM; Bays HE; Granowitz C; Doyle RT; Juliano RA; Philip S
Am J Cardiol; 2019 Sep; 124(5):696-701. PubMed ID: 31277790
[TBL] [Abstract][Full Text] [Related]
19. Omega-3 carboxylic acids (Epanova): a review of its use in patients with severe hypertriglyceridemia.
Blair HA; Dhillon S
Am J Cardiovasc Drugs; 2014 Oct; 14(5):393-400. PubMed ID: 25234378
[TBL] [Abstract][Full Text] [Related]
20. A double-blind, double-dummy, randomized, placebo-controlled trial to evaluate the effect of statin therapy on triglyceride levels in Mexican hypertriglyceridemic patients.
Talavera JO; Martinez G; Cervantes JL; Marin JA; Rodriguez-Briones I; Gonzalez JG; Ocampo R; Sanchez-Mijangos H; Bernal-Rosales LP; Polanco A
Curr Med Res Opin; 2013 Apr; 29(4):379-86. PubMed ID: 23323877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]